Skip to content

Study on biomarkers of targeted therapy for atopic dermatitis

Study on biomarkers of targeted therapy for atopic dermatitis

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300076625
Enrollment
Unknown
Registered
2023-10-13
Start date
2022-01-01
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atopic dermatitis

Interventions

Sponsors

Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with atopic dermatitis: ? Hanifin Rajka diagnostic criteria for atopic dermatitis were met; ? No limit on age, male or female; ? AD patients who need to use biological agents/JAK inhibitors after normal outpatient diagnosis and treatment, and agree to participate in this study and sign; ? No intestinal and other allergic diseases; ? No antibiotics were taken within one month before enrollment, and probiotics or probiotics were not used within one month before the start of the test; ? No yoghurt, pickles or cheese were consumed within 3 days before sample collection; Inclusion criteria for the healthy control group: ? Patients with no history of eczema or other autoimmune skin diseases; ? Age and gender are not limited; ? No intestinal or other allergic diseases; ? I did not take any antibiotics within one month before enrollment, and did not use probiotics or probiotic preparations within one month before the start of the experiment; ? Not consuming yogurt, kimchi, or cheese within 3 days prior to sample collection;

Exclusion criteria

Exclusion criteria: Exclusion criteria for patients with atopic dermatitis: ? Patients who cannot cooperate with specimen retention and follow-up; ? Patients whose specimens are not qualified; ? Pregnancy or lactation; ? Patients with autoimmune diseases and chronic inflammatory diseases; ? Serious hereditary skin diseases and serious health problems that may confuse AD diagnosis or rash judgment; ? Allergic to any component of biological agents or JAK inhibitors; Exclusion criteria for the healthy control group: ? Patients who cannot cooperate with specimen retention and follow-up; ? Patients with unqualified specimen retention; ? Pregnancy or lactation period;

Design outcomes

Primary

MeasureTime frame
Eczema area and severity index;Intestinal flora;Cytokines and chemokines;IGA;

Secondary

MeasureTime frame
PP-NRS;POEM;DLQI;

Countries

China

Contacts

Public ContactLi Jie

Xiangya Hospital of Central South University

xylijie@csu.edu.cn+86 136 7732 7943

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026